ARTO NCT03449719
ForOligometastatic CRPC, ≤3 nonvisceral lesions, starting first-line abiraterone
92% v 68.3%
OR 5.34 (95% CI, 2.05 to 13.88; P = .001)
TL;DRAdding SBRT to abiraterone in oligometastatic CRPC: biochemical response 92% vs 68.3%, OR 5.34; PFS HR 0.35.
Surfaced from a review's discussed trials
The systemic backbone is fixed (AAP both arms), so the entire effect is RT-attributable: PFS HR 0.35 for ablating ≤3 nonvisceral lesions. That isolates the metastasis-directed question in castration-resistant disease, where prior randomized MDT data sit in the hormone-sensitive setting. Dose and fractionation are not in the source text, which limits direct transfer.
In castration-resistant pts with three or fewer nonvisceral metastases starting first-line abiraterone, this supports considering metastasis-directed SBRT concurrently; it does not extend to visceral, higher-volume, or hormone-sensitive metastatic disease.
The randomized contrast is SBRT alone, since AAP is fixed in both arms: PFS HR 0.35 (95% CI 0.21-0.57) for ablating ≤3 nonvisceral lesions. This moves the offer-MDT-at-castration-resistance decision, though dose, fractionation and target volume are absent from the source text, so technique transfer cannot be judged.
Systemic management is unchanged: both arms received first-line abiraterone and prednisone, so nothing here alters drug choice or sequencing. The read is whether to involve radiation oncology at the start of AAP in low-volume CRPC, with progression deferred (HR 0.35) but no survival endpoint reported.
Also covered Jul 7
8 details 5 trials watching
Multicenter randomized phase 2, 1:1 allocation, N=157 enrolled January 2019 to September 2022. Median follow-up not reported in source.
Oligometastatic castrate-resistant prostate cancer, defined as three or fewer nonvisceral metastatic lesions. Visceral disease excluded by definition.
Both arms received abiraterone acetate and prednisone (AAP). The experimental arm added concomitant SBRT, so AAP is a fixed backbone and the randomized contrast is radiotherapy alone.
SBRT to all sites of disease, delivered concomitantly with AAP. Dose, fractionation and target-volume detail are not reported in the source text, which gates how directly the result transfers to a given SBRT practice.
Primary: biochemical response, PSA decrease ≥50% from baseline at 6 months. Secondary: complete biochemical response (PSA <0.2 ng/mL at 6 months) and progression-free survival. No survival endpoint reported.
No toxicity reported in source, so the added burden of ablating up to three lesions is unquantified. PSA endpoints are mechanically sensitive to removing PSA-producing deposits, and the 6-month timepoint precedes any durability read.
STOMP and ORIOLE established the randomized signal for metastasis-directed therapy in hormone-sensitive oligometastatic disease. ARTO's addition is that the signal persists on an ARSI backbone in castration-resistant disease, a setting those trials did not test.
The PFS HR 0.35 is the more meaningful of the two results, since it is less mechanically coupled to ablating PSA-producing lesions than the primary endpoint. What remains unsettled is whether deferring progression on an ARSI translates into anything durable, which a phase 2 sized for a 6-month PSA readout cannot answer.
Randomized phase 2 with a 6-month PSA surrogate primary endpoint; no OS, no reported toxicity, and phase 3 confirmation in CRPC is absent.
- Does the PFS benefit translate to overall survival n=102 · primary completion 2027-04 · randomised SBRT in oligomet CRPC on ARSi backbonerecruiting Metastasis-directed Therapy in Oligoprogressive Castration-refractory Prostate Cancer Phase 3n=246 · primary completion 2029-01 · phase 3 MDT in castration-refractory, up to 5 lesions
- SBRT-attributable toxicity when ablating up to three sites recruiting SBRT Versus Hypofractionated Radiotherapy for Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma Phase 3n=118 · primary completion 2030-01 · phase 3 powered on SBRT toxicity vs hypofx RTrecruiting Fractionated Stereotactic Radiotherapy Plus Second-generation Antiandrogen for Oligometastatic Castration-resistant Prostate Cancer Patients. Phase 2n=51 · primary completion 2030-05 · SBRT + abiraterone/enza in mCRPC, safety endpoint
- Whether benefit holds beyond three lesions recruiting HIghly MetAstatic Life Prolonging Therapy-Resistant Prostate Cancer: Role of Stereotactic Radiotherapy for Bone and Lymph Node Metastases (HIMARS) Phase NAn=18 · primary completion 2028-05 · volume-escalated SRT in high-volume mets, MTV endpoint
📚 Sources · 📄 1 paper
Abstract
The longer read
The design decision that makes ARTO worth reading is that both arms received the same systemic therapy. Abiraterone plus prednisone is fixed, randomization applies only to whether the three or fewer nonvisceral deposits are ablated, and so every part of the effect is attributable to radiotherapy. Trials of metastasis-directed therapy frequently confound the local question with a change in systemic management, and this one does not.
Where it sits against prior randomized data is the second point. STOMP and ORIOLE tested metastasis-directed therapy in hormone-sensitive oligometastatic disease, and both reported a benefit on progression-based endpoints in populations still responsive to androgen deprivation. ARTO asks whether the same holds once resistance has emerged and an androgen receptor pathway inhibitor is the backbone. A reasonable prior would be that the benefit shrinks in castration-resistant disease, since the biology that produced resistance is less likely to be confined to the visible lesions. The reported PFS hazard ratio of 0.35 does not look attenuated relative to that prior, which is the result's genuinely informative feature.
The primary endpoint is the weakest part of the argument, and it is worth being explicit about why. Biochemical response was defined as a PSA decrease of at least 50 percent from baseline at six months. Ablating PSA-producing deposits lowers PSA by direct mechanism, independent of any effect on the disease course, so a difference of 92 percent versus 68.3 percent should not move a reader's confidence very far on its own. The same objection applies with more force to complete biochemical response at a threshold of 0.2 ng/mL, where the arm that had its measurable lesions treated is structurally advantaged. The progression-free survival result carries the weight here, and it is a secondary endpoint in a phase 2 trial, which is precisely the configuration that most often fails to replicate at scale.
Two things absent from the source constrain what a radiation oncologist can do with this. Dose, fractionation and target volume are not reported, so whether the result transfers to a given SBRT practice cannot be assessed from this text. Toxicity is likewise unreported, which matters more than usual when the intervention is ablating up to three separate sites in men who will remain on systemic therapy afterward. The decision this study informs, whether to offer metastasis-directed therapy at the point of castration resistance rather than waiting, turns partly on that toxicity number, and it is not here.
For the result to be wrong in the way phase 2 results are usually wrong, the progression-free survival separation would have to reflect the endpoint's dependence on the same imaging and PSA signals that treatment directly alters, rather than a real change in disease trajectory. That is a live possibility and the trial's size does not exclude it. What ARTO establishes is that the question is worth a properly powered trial in castration-resistant disease with a survival endpoint and reported late toxicity, not that the practice should change now.